Abbott Laboratories

ABT has staged a medium-term advance from its lows but recent price action—marked by long upper wicks on declining volume and an RSI rollover from overbought—signals waning upside momentum. Although the medium-term bias remains bullish within a Stage 3 context, short-term timing is unfavorable. A pullback into the rising 9/20 EMAs now presents a more favorable entry zone than chasing current highs.

• ↑Q2 revenue $10.5B (+4.8% YoY) accelerated to mid-single digits
• ↑Declared 410th consecutive $0.63 dividend, yielding 0.88%
• ↓Weak profitability factors and low earnings yield pressure returns